MedTrace Logo

A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Heath

NCT04794218 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2024-01-18

No results posted yet for this study

Summary

A Phase 1 Randomized, Double-blinded, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Health

Conditions

  • Lassa Fever
  • Lassa Virus Infection

Interventions

DRUG

rVSV∆G-LASV-GPC

2 × 10\^4 pfu delivered intramuscularly

DRUG

rVSV∆G-LASV-GPC

2 × 10\^5 pfu delivered intramuscularly

DRUG

rVSV∆G-LASV-GPC

2 × 10\^6 pfu delivered intramuscularly

DRUG

rVSV∆G-LASV-GPC

2 × 10\^7 pfu delivered intramuscularly

OTHER

Placebo/Diluent

N/A delivered intramuscularly

Sponsors & Collaborators

  • George Washington University

    collaborator OTHER

  • Brigham and Women's Hospital

    collaborator OTHER

  • Redemption Hospital

    collaborator UNKNOWN

  • East-West Medical Research Institute

    collaborator UNKNOWN

  • International AIDS Vaccine Initiative

    lead NETWORK

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
51 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-23
Primary Completion
2023-12-19
Completion
2024-03-31
FDA Drug
Yes

Countries

  • United States
  • Liberia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04794218 on ClinicalTrials.gov